Members are reminded that the end of the transition period for existing products that contain inorganic magnesium salts and Andrographis is 28 Feb 2022. Sponsors have been provided a 12-month transition period from 1 March 2021 to bring existing listed medicine products into compliance:

 - Existing products that contain Andrographis must include a taste disturbance warning from March 1 2022.

 - Existing products that contain inorganic magnesium salts must include a laxative warning on labels from 1 March 2022 when the magnesium meets the requirements of the Permissible Ingredients Determination.

Please read today’s technical alert for more details.